{
    "info": {
        "nct_id": "NCT05563272",
        "official_title": "Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX",
        "inclusion_criteria": "* Written and voluntarily given Informed Consent.\n* Male or female ≥18 years of age at time of consent.\n* Have the capacity to understand the study and be willing and able to comply with all protocol requirements.\n* Participants must have histologically or cytologically proven solid tumors of the following types, but not limited to:\n\n  * cervical cancer\n  * colorectal cancer\n  * esophageal cancer (esophageal SCC and esophageal/esophagogastric junction adenocarcinoma)\n  * gastric cancer (gastric adenocarcinoma)\n  * glioblastoma multiforme\n  * head and neck cancer (head and neck SCC and nasopharyngeal carcinoma)\n  * liver cancer (cholangiocarcinoma and hepatocellular carcinoma)\n  * lung cancer (non-small cell and small cell)\n  * ovarian cancer (epithelial ovarian carcinoma)\n  * pancreatic cancer (pancreatic ductal adenocarcinoma)\n  * soft tissue sarcoma\n* At least one non-CNS, measurable target lesion as per RECIST 1.1 documented at conventional imaging, performed within 30 days prior to Day 0.\n* Participant agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form (ICF) until completion of the last study visit.\n* Negative serum pregnancy tests in female patients of childbearing potential at screening and confirmation of negative pregnancy test result from urine within24 hours prior to receiving investigational product. Female patients of non-child-bearing potential must provide evidence by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n  * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.\n  * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation\n* For all participants, consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-girentuximab administration.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 95 Years",
        "exclusion_criteria": "* Exposure to murine or chimeric antibodies within the last 5 years.\n* Previous administration of any radionuclide within 10 half-lives (of the radionuclide) prior to the intended administration of 89Zr-girentuximab(i.e., within 10 half-lives of Day0).\n* Exposure to any CAIX targeting compound (diagnostic/therapeutic) in the last 3 months\n* Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the Investigator.\n* Any clinically significant abnormalities detected during screening laboratory tests or physical exam that in the opinion of the Investigator would adversely affect the participants ability to participate in the study. Principal Investigator to assess patient suitability for inclusion based on pathology and tumor type.\n* Mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.\n* Exposure to any antineoplastic treatment within 14 days from the date of planned administration of 89Zr-girentuximab(i.e. within 14 days of Day 0).\n* Women who are pregnant or breastfeeding.\n* Known allergy, hypersensitivity, or intolerance to girentuximab, DFO (desferrioxamine),or any of the components of the investigationalagent.10.Renal insufficiency with glomerular filtration rate (GFR) ≤ 45 millilitres/min/1.73m2\n* Vulnerable patients (e.g. being in detention).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Written and voluntarily given Informed Consent.",
            "criterions": [
                {
                    "exact_snippets": "Written and voluntarily given Informed Consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        },
                        {
                            "requirement_type": "voluntariness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female ≥18 years of age at time of consent.",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have the capacity to understand the study and be willing and able to comply with all protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Have the capacity to understand the study",
                    "criterion": "capacity to understand the study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing and able to comply with all protocol requirements",
                    "criterion": "willingness and ability to comply with protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have histologically or cytologically proven solid tumors of the following types, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically proven solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* cervical cancer",
            "criterions": [
                {
                    "exact_snippets": "cervical cancer",
                    "criterion": "cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* colorectal cancer",
            "criterions": [
                {
                    "exact_snippets": "colorectal cancer",
                    "criterion": "colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* esophageal cancer (esophageal SCC and esophageal/esophagogastric junction adenocarcinoma)",
            "criterions": [
                {
                    "exact_snippets": "esophageal cancer (esophageal SCC and esophageal/esophagogastric junction adenocarcinoma)",
                    "criterion": "esophageal cancer",
                    "requirements": [
                        {
                            "requirement_type": "subtypes",
                            "expected_value": [
                                "esophageal SCC",
                                "esophageal/esophagogastric junction adenocarcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* gastric cancer (gastric adenocarcinoma)",
            "criterions": [
                {
                    "exact_snippets": "gastric cancer (gastric adenocarcinoma)",
                    "criterion": "gastric cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* glioblastoma multiforme",
            "criterions": [
                {
                    "exact_snippets": "glioblastoma multiforme",
                    "criterion": "glioblastoma multiforme",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* head and neck cancer (head and neck SCC and nasopharyngeal carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "head and neck cancer",
                    "criterion": "head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "head and neck SCC",
                    "criterion": "head and neck SCC",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nasopharyngeal carcinoma",
                    "criterion": "nasopharyngeal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* liver cancer (cholangiocarcinoma and hepatocellular carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "liver cancer (cholangiocarcinoma and hepatocellular carcinoma)",
                    "criterion": "liver cancer",
                    "requirements": [
                        {
                            "requirement_type": "subtypes",
                            "expected_value": [
                                "cholangiocarcinoma",
                                "hepatocellular carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* lung cancer (non-small cell and small cell)",
            "criterions": [
                {
                    "exact_snippets": "lung cancer (non-small cell and small cell)",
                    "criterion": "lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "non-small cell",
                                "small cell"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ovarian cancer (epithelial ovarian carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "ovarian cancer (epithelial ovarian carcinoma)",
                    "criterion": "ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "epithelial ovarian carcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* pancreatic cancer (pancreatic ductal adenocarcinoma)",
            "criterions": [
                {
                    "exact_snippets": "pancreatic cancer (pancreatic ductal adenocarcinoma)",
                    "criterion": "pancreatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "pancreatic ductal adenocarcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* soft tissue sarcoma",
            "criterions": [
                {
                    "exact_snippets": "soft tissue sarcoma",
                    "criterion": "soft tissue sarcoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one non-CNS, measurable target lesion as per RECIST 1.1 documented at conventional imaging, performed within 30 days prior to Day 0.",
            "criterions": [
                {
                    "exact_snippets": "At least one non-CNS, measurable target lesion",
                    "criterion": "non-CNS measurable target lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "documented at conventional imaging",
                    "criterion": "conventional imaging documentation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 30 days prior to Day 0",
                    "criterion": "imaging timing",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to Day 0"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form (ICF) until completion of the last study visit.",
            "criterions": [
                {
                    "exact_snippets": "Participant agrees not to participate in another interventional study",
                    "criterion": "participation in another interventional study",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.",
            "criterions": [
                {
                    "exact_snippets": "Post-menopausal defined as aged more than 50 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "comparison",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for at least 12 months",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cessation of all exogenous hormonal treatments",
                    "criterion": "exogenous hormonal treatments",
                    "requirements": [
                        {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.",
            "criterions": [
                {
                    "exact_snippets": "Women under 50 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for 12 months or more",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cessation of exogenous hormonal treatments",
                    "criterion": "exogenous hormonal treatment cessation",
                    "requirements": [
                        {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution",
                    "criterion": "hormone levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range for the institution"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation",
            "criterions": [
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by hysterectomy",
                    "criterion": "irreversible surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "hysterectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by ... bilateral oophorectomy",
                    "criterion": "irreversible surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "bilateral oophorectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by ... bilateral salpingectomy",
                    "criterion": "irreversible surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "bilateral salpingectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization ... but not tubal ligation",
                    "criterion": "irreversible surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "not tubal ligation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For all participants, consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-girentuximab administration.",
            "criterions": [
                {
                    "exact_snippets": "consent to practice double-barrier contraception",
                    "criterion": "double-barrier contraception",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "until a minimum of 42 days after 89Zr-girentuximab administration",
                    "criterion": "duration of contraception",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 95 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 95 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 95,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Exposure to murine or chimeric antibodies within the last 5 years.",
            "criterions": [
                {
                    "exact_snippets": "Exposure to murine or chimeric antibodies within the last 5 years.",
                    "criterion": "exposure to murine antibodies",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Exposure to murine or chimeric antibodies within the last 5 years.",
                    "criterion": "exposure to chimeric antibodies",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous administration of any radionuclide within 10 half-lives (of the radionuclide) prior to the intended administration of 89Zr-girentuximab(i.e., within 10 half-lives of Day0).",
            "criterions": [
                {
                    "exact_snippets": "Previous administration of any radionuclide within 10 half-lives",
                    "criterion": "previous administration of radionuclide",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "half-lives"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exposure to any CAIX targeting compound (diagnostic/therapeutic) in the last 3 months",
            "criterions": [
                {
                    "exact_snippets": "Exposure to any CAIX targeting compound (diagnostic/therapeutic)",
                    "criterion": "exposure to CAIX targeting compound",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic)",
                    "criterion": "serious non-malignant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "that may interfere with the objectives of the study or with the safety or compliance of the subject",
                    "criterion": "interference with study objectives, safety, or compliance",
                    "requirements": [
                        {
                            "requirement_type": "potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as judged by the Investigator",
                    "criterion": "investigator's judgment",
                    "requirements": [
                        {
                            "requirement_type": "authority",
                            "expected_value": "Investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any clinically significant abnormalities detected during screening laboratory tests or physical exam that in the opinion of the Investigator would adversely affect the participants ability to participate in the study. Principal Investigator to assess patient suitability for inclusion based on pathology and tumor type.",
            "criterions": [
                {
                    "exact_snippets": "clinically significant abnormalities detected during screening laboratory tests",
                    "criterion": "abnormalities in screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "significance",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant abnormalities detected during ... physical exam",
                    "criterion": "abnormalities in physical exam",
                    "requirements": [
                        {
                            "requirement_type": "significance",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "Principal Investigator to assess patient suitability for inclusion based on pathology",
                    "criterion": "pathology",
                    "requirements": [
                        {
                            "requirement_type": "suitability for inclusion",
                            "expected_value": "assessed by Principal Investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "Principal Investigator to assess patient suitability for inclusion based on ... tumor type",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "suitability for inclusion",
                            "expected_value": "assessed by Principal Investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.",
            "criterions": [
                {
                    "exact_snippets": "Mental impairment that may compromise the ability to give Informed Consent",
                    "criterion": "mental impairment",
                    "requirements": [
                        {
                            "requirement_type": "impact on informed consent",
                            "expected_value": "compromise"
                        }
                    ]
                },
                {
                    "exact_snippets": "Mental impairment that may ... comply with the requirements of the study",
                    "criterion": "mental impairment",
                    "requirements": [
                        {
                            "requirement_type": "impact on study compliance",
                            "expected_value": "compromise"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exposure to any antineoplastic treatment within 14 days from the date of planned administration of 89Zr-girentuximab(i.e. within 14 days of Day 0).",
            "criterions": [
                {
                    "exact_snippets": "Exposure to any antineoplastic treatment within 14 days from the date of planned administration of 89Zr-girentuximab",
                    "criterion": "exposure to antineoplastic treatment",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vulnerable patients (e.g. being in detention).",
            "criterions": [
                {
                    "exact_snippets": "Vulnerable patients (e.g. being in detention)",
                    "criterion": "vulnerability",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "vulnerable"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Negative serum pregnancy tests in female patients of childbearing potential at screening and confirmation of negative pregnancy test result from urine within24 hours prior to receiving investigational product. Female patients of non-child-bearing potential must provide evidence by fulfilling one of the following criteria at screening:",
            "criterions": [
                {
                    "exact_snippets": "Negative serum pregnancy tests in female patients of childbearing potential at screening",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation of negative pregnancy test result from urine within 24 hours prior to receiving investigational product",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Female patients of non-child-bearing potential must provide evidence by fulfilling one of the following criteria at screening",
                    "criterion": "non-child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": "fulfilling one of the following criteria"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Known allergy, hypersensitivity, or intolerance to girentuximab, DFO (desferrioxamine),or any of the components of the investigationalagent.10.Renal insufficiency with glomerular filtration rate (GFR) ≤ 45 millilitres/min/1.73m2",
            "criterions": [
                {
                    "exact_snippets": "Known allergy, hypersensitivity, or intolerance to girentuximab",
                    "criterion": "allergy, hypersensitivity, or intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergy, hypersensitivity, or intolerance to ... DFO (desferrioxamine)",
                    "criterion": "allergy, hypersensitivity, or intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergy, hypersensitivity, or intolerance to ... any of the components of the investigational agent",
                    "criterion": "allergy, hypersensitivity, or intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Renal insufficiency with glomerular filtration rate (GFR) ≤ 45 millilitres/min/1.73m2",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 45,
                                "unit": "millilitres/min/1.73m2"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}